In a report issued on December 8, Arnaud Girod from Kepler Capital maintained a Hold rating on Argenx Se (ARGX), with a price target of EUR200.00. The company’s shares closed last Wednesday at $270.09, close to its 52-week high of $292.58.
According to TipRanks.com, Girod is ranked #6643 out of 7138 analysts.
Currently, the analyst consensus on Argenx Se is a Moderate Buy with an average price target of $276.97, which is a -2.3% downside from current levels. In a report issued on November 24, H.C. Wainwright also maintained a Hold rating on the stock with a $265.00 price target.
See today’s analyst top recommended stocks >>
Argenx Se’s market cap is currently $13.62B and has a P/E ratio of -33.00. The company has a Price to Book ratio of 7.63.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
